Published in J Med Chem on July 23, 2014
Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer (2016) 1.31
Two in one: improving synthetic long peptide vaccines by combining antigen and adjuvant in one molecule. Oncoimmunology (2014) 0.78
The Novel Toll-Like Receptor 2 Agonist SUP3 Enhances Antigen Presentation and T Cell Activation by Dendritic Cells. Front Immunol (2017) 0.75
TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients. Oncotarget (2016) 0.75
A role for Piwi and piRNAs in germ cell maintenance and transposon silencing in Zebrafish. Cell (2007) 6.31
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med (2009) 5.79
CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science (2003) 5.22
Dendritic cell immunotherapy: mapping the way. Nat Med (2004) 4.28
CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J Clin Invest (2008) 3.11
Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. Proc Natl Acad Sci U S A (2005) 2.70
CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis. Arthritis Rheum (2003) 2.68
The inhibiting Fc receptor for IgG, FcγRIIB, is a modifier of autoimmune susceptibility. J Immunol (2011) 2.44
Asymmetric proteasome segregation as a mechanism for unequal partitioning of the transcription factor T-bet during T lymphocyte division. Immunity (2011) 2.34
Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr Opin Immunol (2004) 2.27
Proteasome inhibitors: an expanding army attacking a unique target. Chem Biol (2012) 2.26
Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res (2008) 2.06
Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res (2009) 2.04
MHC II in dendritic cells is targeted to lysosomes or T cell-induced exosomes via distinct multivesicular body pathways. Traffic (2009) 1.98
High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res (2007) 1.96
Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol (2002) 1.93
Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res (2004) 1.90
Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol (2011) 1.71
Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci U S A (2010) 1.67
Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J Immunol (2002) 1.66
Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res (2008) 1.66
Analysis of protease activity in live antigen-presenting cells shows regulation of the phagosomal proteolytic contents during dendritic cell activation. J Exp Med (2002) 1.64
Thioglycosides in sequential glycosylation strategies. Chem Soc Rev (2005) 1.60
Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm. Cancer Res (2010) 1.59
Microreactors as tools for synthetic chemists-the chemists' round-bottomed flask of the 21st century? Chemistry (2006) 1.56
Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol (2009) 1.56
A fluorescent broad-spectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo. Chem Biol (2006) 1.54
CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol (2007) 1.54
Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci U S A (2007) 1.53
Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites. Chem Biol (2009) 1.47
The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites. J Biol Chem (2003) 1.46
Differential kinetics of antigen-specific CD4+ and CD8+ T cell responses in the regression of retrovirus-induced sarcomas. J Immunol (2002) 1.46
Synthesis of pH-activatable red fluorescent BODIPY dyes with distinct functionalities. Org Lett (2011) 1.44
Ph2SO/Tf2O: a powerful promotor system in chemoselective glycosylations using thioglycosides. Org Lett (2003) 1.42
Glycosphingolipids--nature, function, and pharmacological modulation. Angew Chem Int Ed Engl (2009) 1.41
Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Cancer Res (2003) 1.40
Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin Cancer Res (2011) 1.39
Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin Cancer Res (2005) 1.38
CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci U S A (2002) 1.34
Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Clin Cancer Res (2005) 1.30
Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication. J Immunol (2004) 1.29
Development of adamantan-1-yl-methoxy-functionalized 1-deoxynojirimycin derivatives as selective inhibitors of glucosylceramide metabolism in man. J Org Chem (2007) 1.28
Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells. J Exp Med (2007) 1.28
Muscle wasting in aged, sarcopenic rats is associated with enhanced activity of the ubiquitin proteasome pathway. J Biol Chem (2010) 1.28
Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. Eur J Immunol (2010) 1.27
Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res (2009) 1.27
Ultrasensitive in situ visualization of active glucocerebrosidase molecules. Nat Chem Biol (2010) 1.26
Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes. PLoS One (2011) 1.26
Chemistry in living cells: detection of active proteasomes by a two-step labeling strategy. Angew Chem Int Ed Engl (2003) 1.25
Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity. Proc Natl Acad Sci U S A (2009) 1.24
Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes. Nat Immunol (2010) 1.24
Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells. J Biol Chem (2007) 1.23
Therapeutic cancer vaccines. J Clin Invest (2015) 1.23
New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer. J Transl Med (2012) 1.23
NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol Immunol (2008) 1.23
Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res (2002) 1.22
Crystal structure of HslUV complexed with a vinyl sulfone inhibitor: corroboration of a proposed mechanism of allosteric activation of HslV by HslU. J Mol Biol (2002) 1.21
Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. J Immunol (2006) 1.19
The minor histocompatibility antigen HA-3 arises from differential proteasome-mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein. Blood (2003) 1.18
Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects. Clin Cancer Res (2013) 1.18
Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat Med (2006) 1.17
A modular strategy toward the synthesis of heparin-like oligosaccharides using monomeric building blocks in a sequential glycosylation strategy. J Am Chem Soc (2005) 1.17
Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunol Rev (2002) 1.16
Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors. PLoS One (2011) 1.16
Ins and outs of dendritic cells. Int Arch Allergy Immunol (2006) 1.16
Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur J Immunol (2008) 1.16
Human papillomavirus (HPV) upregulates the cellular deubiquitinase UCHL1 to suppress the keratinocyte's innate immune response. PLoS Pathog (2013) 1.15
Recognition of base J in duplex DNA by J-binding protein. J Biol Chem (2001) 1.15
The conformation of neurotensin bound to its G protein-coupled receptor. Proc Natl Acad Sci U S A (2003) 1.14
Vaccine-induced effector-memory CD8+ T cell responses predict therapeutic efficacy against tumors. J Immunol (2012) 1.14
N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors. Neuropsychopharmacology (2006) 1.14
Design and development of synthetic peptide vaccines: past, present and future. Expert Rev Vaccines (2007) 1.14
Structure and reactivity of an asymmetric complex between HslV and I-domain deleted HslU, a prokaryotic homolog of the eukaryotic proteasome. J Mol Biol (2003) 1.13
Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib. Chem Biol (2011) 1.13